ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

クロルフェニラミン

(+-)-Chlorpheniramine

HCID 2725
ノート反応
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
113-92-8
標準SMILES
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
InChIKey
SOYKEARSMXGVTM-UHFFFAOYSA-N
分子式
C16H19ClN2
平均分子量
274.79 g/mol
単同位体質量
274.1236763

概要

Chlorphenamine is a tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. It has a role as an antidepressant, a H1-receptor antagonist, a histamine antagonist, an anti-allergic agent, a serotonin uptake inhibitor and an antipruritic drug. It is a member of pyridines, a tertiary amino compound and a member of monochlorobenzenes.

名称と識別子

優先名称
(+-)-Chlorpheniramine
IUPAC
3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
現地名
クロルフェニラミン
英語名
Chloropheniramine
分子式
C16H19ClN2
分子量
274.79

名称と別名

chlorpheniramineChlorphenamine132-22-9ChlorophenylpyridamineHaynonClorfeniraminaAllergicanAllergisanClorfenaminaHistadurChloropheniramineChlorprophenpyridamine
名称をさらに表示
クロルフェニラミンクロルフェナミンChlorphenaramine(±)-ChlorpheniamineChloropheniramine-D4Brompheniramine EP Impurity ABrompheniramine maleate EP Impurity A2-Pyridinepropanamine, g-(4-chlorophenyl)-N,N-dimethyl(s) -y-(4-chlorophenyl) -N, N- Dimethyl -2-pyridinepropaneamine Base (or) Chlorpheniramine base
ChloroprophenpyridamineChlorpheniraminumChlorphenaminum4-ChloropheniramineClofeniramina3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amineChlorphenamin1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane

データベース識別子

CAS
113-92-8、132-22-9
PubChem CID
2725
DTXSID

物性

構造計算による物性

XLogP
3.4
極性表面積
16.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
5
重原子数
19
形式電荷
0
複雑度
249

実験および物理化学的性質

Chemical ClassesPharmaceutical
DrugsPharmaceuticals
LogP3.66
Color/FormOILY LIQUID
Solubility · 2 件

UV max absorption (water): 261 nm (E=5760), Solubility in mg/ml at 25 °C: Ethanol 330; chloroform 240; water 160; methanol 130; pH of a 2% aqueous solution about 5 /Maleate/

160.0 mg/mL at 25 °C

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antihistamines; Antipruritics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Boiling Point142 °C @ 1.0 MM HG
Melting Point130 - 135 °C
Refractive IndexBOX LIKE PRISMS & IRREGULAR FRAGMENTS; INDEX OF REFRACTION: 1.533 (ALPHA); 1.668 (BETA; INTERMEDIATE INDEX); LESS THAN 1.734 (GAMMA; INCLINED) /MALEATE/

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Regulatory InformationChlorphenamine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Special ReportsDHHS/NTP; Toxicology & Carcinogenesis Studies of Chlorpheniramine maleate in F344/N Rats and B6C3F1 Mice Technical Report Series No. 317 (1986) NIH Publication No. 86-2573

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

Concurrent use /of ototoxic medications/ with antihistamines may mask the symptoms of ototoxicity such as tinnitus, dizziness, or vertigo. /Antihistamines/

Concurrent use of monoamine oxidase (MAO) inhibitors with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines; concurrent use is not recommended. /Antihistamines/

Concurrent use /with alcohol or other CNS depression-producing medications/ may potentiate the CNS depressant effects of either these medications or antihistamines; also, concurrent use of maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either antihistamines or these medications. /Antihistamines/

化学と産業

薬理情報

ATC Code · 3 件

R06AB54

R - Respiratory system

QR - Respiratory system

Protein Binding72%
Pharmacodynamics · 1 件

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H<sub>1</sub>-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Chlorpheniramine, is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Mechanism of Action · 6 件

Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/

H1 antagonists inhibit most responses of smooth muscle to histamine. Antagonism of the constrictor action of histamine on respiratory smooth muscle is easily shown in vivo and in vitro. /Histamine Antagonists: H1 Antagonists/

H1 antagonists strongly block the action of histamine that results in increased permeability and formation of edema and wheal. /Histamine Antagonists: H1 Antagonists/

関連反応

4 件
反応記録を作成
HRID 388180 の反応式
HRID 388180生成物としてuspto-grants-2013_02
HRID 1194278 の反応式
HRID 1194278生成物としてuspto-grants-1989_03
HRID 1710296 の反応式
HRID 1710296生成物としてuspto-grants-2010_09
HRID 1741557 の反応式
HRID 1741557生成物としてuspto-grants-1994_08

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
DTXSID0022804
ChEMBL
CHEMBL505
ChEBI
CHEBI:52010
UNII
3U6IO1965U
EC Number
205-054-0
Nikkaji
J441.686D、J5.570K
Physical Description
Solid
Stability/Shelf LifeSENSITIVE TO LIGHT. /MALEATE/

物理化学的性質

融点
25 °C · 25°C
沸点
1 · bp1.0 142°
比重(密度)
1.0895 · 1.0895 (rough estimate)
屈折率
1.5749 · 1.5749 (estimate)
溶解性
DMSO (Slightly), Methanol (Slightly)
外見
Oil
酸解離定数(Pka)
9.33 · 9.33±0.28(Predicted)
色
Colourless to Light Yellow
水溶解度
5.496 g/L · 5.496g/L(37.5℃)
InChI
InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
InChIKey
SOYKEARSMXGVTM-UHFFFAOYSA-N
SMILES
C(C1N=CC=CC=1)(C1C=CC(Cl)=CC=1)CCN(C)C
EPAの化学物質情報
Chlorpheniramine (132-22-9)

Anticholinergic effects may be potentiated when /anticholinergics or other medications with anticholinergic activity/ are used concurrently with antihistamines; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy. /Antihistamines/

Concurrent use /of other photosensitizing medications/ with antihistamines may cause additive photosensitizing effects. /Antihistamines/

Health EffectsChlorpheniramine posesses serotonergic and norepinephrinergic effects. It has been shown to work as a serotonin-norepinephrine reuptake inhibitor or SNRI. [Wikipedia]
Exposure RoutesWell absorbed in the gastrointestinal tract.
Toxicity SummaryChlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Ongoing Test Status · 1 件

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. /Chlorpheniramine maleate/ [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=113-92-8]

Human Toxicity Excerpts · 5 件

SYMPTOMATOLOGY: 1. CENTRAL NERVOUS DEPRESSION IS USUALLY DOMINANT REACTION IN ADULTS; IT IS EVIDENCED BY DROWSINESS, LETHARGY, FATIGUE, HYPNOSIS, & COMA. RELATED NERVOUS SYMPTOMS INCL VERTIGO, ATAXIA, TINNITUS, & BLURRED VISION. /ANTIHISTAMINICS/

SYMPTOMATOLOGY: 2. CENTRAL NERVOUS HYPEREXCITABILITY OFTEN FOLLOWS INITIAL SEDATION; IN CHILDREN EXCITEMENT IS OFTEN FIRST EVIDENCE OF POISONING. STIMULANT PHASE BRINGS TREMORS, ANXIETY, INSOMNIA, EXCITEMENT, HALLUCINATIONS, DELIRIUM, TOXIC PSYCHOSIS & CONVULSIONS... /ANTIHISTAMINICS/

SYMPTOMATOLOGY: 3. DANGEROUS HYPERPYREXIA MAY OCCUR IN POISONED CHILDREN... 4. GASTROINTESTINAL REACTIONS INCL DRY MOUTH, ANOREXIA, NAUSEA, VOMITING, ABDOMINAL DISTRESS, CONSTIPATION, &/OR DIARRHEA. /ANTIHISTAMINICS/

SYMPTOMATOLOGY: 5. TERMINAL PHASE IS ONE OF SEVERE CENTRAL NERVOUS DEPRESSION, WITH DEATH FROM RESP ARREST OR CARDIOVASCULAR COLLAPSE. /ANTIHISTAMINICS/

For more Human Toxicity Excerpts (Complete) data for CHLORPHENIRAMINE (10 total), please visit the HSDB record page.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

chlorpheniramine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 5 件

LARGE DOSES PRODUCE CONVULSIONS IN EXPTL ANIMALS. /ANTIHISTAMINES/

SMALL DOSES OF SOME ANTIHISTAMINICS PRODUCE DEPRESSION, DROWSINESS, SALIVATION & VOMITING. /ANTIHISTAMINICS/

CHLORPHENIRAMINE MALEATE DECR ACETYLCHOLINE LEVEL IN BOTH HEMISPHERES & REST OF BRAIN. RESULTS FOR STYRAMINE ARE ALSO GIVEN.

... H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /Histamine Antagonists: H1 Antagonists/

CHLORPHENIRAMINE MALEATE, AN ANTAGONIST OF HISTAMINE, INHIBITED DEVELOPMENT OF EHRLICH ASCITES CARCINOMA WHEN GIVEN TO MICE ORALLY FOR 10 DAYS, STARTING ON DAY OF TUMOR IMPLANT.

Populations at Special Risk · 2 件

Use is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as central nervous system excitation, and an increased tendency toward convulsions. A paradoxical reaction characterized by hyperexcitability may occur in children taking antihistamines. /Antihistamines/

Dizziness, sedation, confusion, and hypotension may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients are especially susceptible to the anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), of the antihistamines. If these side effects occur and continue or are severe, medication should probably be discontinued. /Antihistamines/

Antidote and Emergency Treatment · 1 件

There is no specific therapy for antihistamine poisoning, and treatment is along general symptomatic and supportive lines. ... Should breathing fail, mech support of ventilation offer safer and ... effective means of maintaining resp than use of analeptics which are prone to initiative or intensify convulsive phase. /Antihistamine/

National Toxicology Program Studies · 1 件

Toxicology and carcinogenesis studies of chlorpheniramine maleate (99% pure) ... were conducted by administering this chemical in deionized water by gavage to 50 male and 50 female F344/N rats and B6C3F1 mice, 5 days/wk for 103 wk. The doses used were: male rats: 0, 15, or 30 mg/kg; female rats: 0, 30, or 60 mg/kg; male mice: 0, 25, or 50 mg/kg; female mice: 0, 100, or 200 mg/kg. ... Under the conditions of these two yr studies, there was no evidence of carcinogenicity for F344/N rats or B6C3F1 mice administered chlorpheniramine maleate in deionized water, 5 days/wk for two yr. Due to high mortality in high dose female rats and high dose male mice, the sensitivity of these groups to detect carcinogenic response was reduced. /The cmpd/ had a proliferative effect on the thyroid gland of female mice, as shown by the increased evidences of follicular cell cysts and hyperplasia in both low dose and high dose groups. /Chlorpheniramine maleate/

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

tsca
TSCA listed
有毒物質データの
132-22-9(Hazardous Substances Data)

Within the vascular tree, the H1 antagonists inhibit both the vasoconstrictor effects of histamine and, to a degree, the more rapid vasodilator effects that are mediated by H1 receptors on endothelial cells. Residual vasodilatation reflects the involvement of H2 receptors on smooth muscle and can be suppressed only by the concurrent administration of an H2 antagonist. Effects of the histamine antagonists on histamine induced changes in systemic blood pressure parallel these vascular effects. /Histamine Antagonists: H1 Antagonists/

Many of the H1 antagonists tend to inhibit responses to acetylcholine that are mediated by muscarinic receptors. These atropine like actions are sufficiently prominent in some of the drugs to be manifest during clinical usage ... . /Histamine Antagonists: H1 Antagonists/

Biological Half-Life · 3 件

21-27 hours

IN MAN...PLASMA T/2 OF CHLORPHENIRAMINE IS...12-15 HR...ALTHOUGH PLASMA LEVELS OF TOTAL RADIOACTIVITY ARE PROLONGED...

Elimination: 14 to 25 hours

Metabolism/Metabolites · 3 件

Primarily hepatic via Cytochrome P450 (CYP450) enzymes.

MAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/

Primarily hepatic via Cytochrome P450 (CYP450) enzymes. Half Life: 21-27 hours

FDA Pharmacological Classification · 5 件

3U6IO1965U

CHLORPHENIRAMINE

Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists

Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist

Chlorpheniramine is a Histamine-1 Receptor Antagonist. The mechanism of action of chlorpheniramine is as a Histamine H1 Receptor Antagonist.

MeSH Pharmacological Classification · 3 件

Agents, usually topical, that relieve itching (pruritus).

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

Absorption, Distribution and Excretion · 4 件

Well absorbed in the gastrointestinal tract.

STUDIES IN MAN & EXPTL ANIMALS INDICATE THAT (3)H-CHLORPHENIRAMINE MALEATE IS RAPIDLY & QUANT ABSORBED FROM GUT. ALTHOUGH PLASMA LEVELS OF TOTAL RADIOACTIVITY ARE PROLONGED, PLASMA T/2 OF CHLORPHENIRAMINE IS ONLY 12-15 HR IN MAN & 3 HR IN DOG. T/2 IN MAN IS ABOUT 3 TIMES LONGER THAN THERAPEUTIC EFFECT...

The H1 antagonists are well absorbed from the GI tract. Following oral administration, peak plasma concn are achieved in 2 to 3 hr and effects usually last 4 to 6 hr; however, some of the drugs are much longer acting ... . /Histamine Antagonists: H1 Antagonists/

H1 blockers are among the many drugs that induce hepatic microsomal enzymes, and they may facilitate their own metabolism. /Histamine Antagonists: H1 Antagonists/

Tissue LocationsEpidermis
Cellular LocationsMembrane
Metabolite PathwaysChlorphenamine H1-Antihistamine Action

用途と製造

Uses · 4 件

MEDICATION

MEDICATION (VET):

Use (kg; approx.) in Germany (2009): >250

Used used in the prevention of the symptoms of allergic conditions such as rhinitis, urticaria, allergy, common cold, asthma and hay fever.

U.S. Imports · 2 件

(1977) 5.0X10+6 G-INCL MALEATE (PRINCPL DISTS)

(1979) 2.0X10+7 G-INCL MALEATE (PRINCPL DISTS)

U.S. Production · 2 件

(1977) 1.68X10+7 GRAMS (MALEATE)

(1978) 2.13X10+7 GRAMS (MALEATE)

Methods of Manufacturing · 2 件

CONDENSATION OF 2-(P-CHLORO-ALPHA-(2-CHLOROETHYL)BENZYL)PYRIDINE WITH DIMETHYLAMINE IN THE PRESENCE OF SODAMIDE

Synthesis.

Formulations/Preparations · 2 件

TABLETS, 4 MG; REPEAT-ACTION TABLETS, 8 & 12 MG, INJECTION; SYRUP /FROM TABLE/

GRADE: USP /MALEATE/

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
General Manufacturing Information · 2 件

2-Pyridinepropanamine, .gamma.-(4-chlorophenyl)-N,N-dimethyl-: INACTIVE

TREATMENT OF BASE WITH EQUIMOLAR PORTION OF MALEIC ACID RESULTS IN FORMATION OF MALEATE. /MALEATE/

応用分野 · 2 件

解説3-(4-chlorophenyl)-N,N-dimethyl-3-(2-pyridyl)propylamine.C16H19ClN2(274.79).クロルフェニラミンは,4-クロロベンジルシアニドと2-クロロピリジンとを縮合させ,これに2-(ジメチルアミノ)エチルクロリドを反応させ,80% H2SO4と加熱すると得られる.油状の液体.沸点142 ℃(0.13 kPa).マレイン酸塩:C16H19ClN2·C4H4O4(390.87)が実用化されている.白色の微細な結晶.融点130~135 ℃.λmax 261 nm.水,エタノール,クロロホルムに可溶.2% 水溶液の pH は約5.強力な抗ヒスタミン薬である.じんましん,枯草熱,皮膚疾患に伴う掻痒(そうよう),アレルギー性鼻炎,血管運動性鼻炎などに投与する.LD50 162 mg/kg(マウス,経口).[CAS 132-22-9][CAS 113-92-8:マレイン酸塩] 森北出版「化学辞典(第2版)

使用Chlorpheniramine is a drug in the class of first-generation antihistamines, used to help alleviate symptoms of allergic reactions potentiated by histamine release. Though it is included in many multisymptom over-the-counter cold relief medications, the Food and Drug Administration (FDA) issued a safety alert in March 2011 detailing some risks associated with these medications. The safety alert also indicated that increased enforcement of FDA laws governing the marketing of these drugs would occur, as many of the products had not been approved in their current formulations for safety, effectiveness, and quality. Chlorpheniramine is commonly used in small-animal veterinary medicine for its antihistaminic/antipruritic effects, especially for the treatment of pruritus in cats, and occasionally as a mild sedative.

上流・下流製品情報

下流製品

デクスクロルフェニラミン

サプライヤー60 社

北京华美互利生物化工010-56205725 · [email protected]
江苏瑞点药业有限公司15896106238 · [email protected]
Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
广州佳途科技股份有限公司81960175 18933936954 · [email protected]
上海泰矶林实业有限公司02150630626 17717886015 · [email protected]
Sinoway Industrial co., ltd.+86-0592-5800732 +86-13806035118 · [email protected]
Syntechem Co.,Ltd[email protected]
上海道鞅科技有限公司QQ:3150471267 13381681725 · [email protected]
上海柯维化学技术有限公司021-64609169 18901607656 · [email protected]
江苏艾康生物医药研发有限公司025-5885952 15955137747 · [email protected]
United Life Science020-82099279 18988941402 · [email protected]
上海钰康生物科技有限公司+86-18930848214 +86-021-56762820 · [email protected]
上海艾梯西生物科技有限公司18721763493
广州济成进出口贸易有限公司13682223272 · [email protected]
佛山宝诺生物科技有限公司0757-85921206 18520245316 · [email protected]
北京伊诺凯科技有限公司15652467323 · [email protected]
成都麦卡希化工有限公司028-85632863 18108198598 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
四川省维克奇生物科技有限公司028-81700200 18116577057 · [email protected]
上海麦克林生化科技股份有限公司15221275939 15221275939 · [email protected]
青岛海智微元生物科技有限公司18317699790 18317699790 · [email protected]
天津阿尔塔科技有限公司022-6537-8550 15522853686 · [email protected]
江苏辉润药业有限公司15715295967; 15715295967 · [email protected]
合肥孚亚生物技术有限公司18096409024 · [email protected]
上海阿拉丁生化科技股份有限公司6206333 13167063860 · [email protected]
陕西缔都医药化工有限公司029-029-81120477 17792793610 · [email protected]
上海源叶生物科技有限公司13636370518 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
陕西萃康医药科技有限公司+86-13119157289; +86-13119157289 · [email protected]
上海超岚化工科技中心(原上海巢莱)0-2022843681 15618226720 · [email protected]
上海乾平生物医药科技有限公司(宁波仓库发货)021-61537865 13585780846 · [email protected]
上海巍涛化工有限公司02150630626 17717886015 · [email protected]
深圳市祥根生物医药有限公司0755-28967200 13631290199 · [email protected]
CSSBIO COMPANY LIMITED0756-8828-007
上海研易宝医药科技有限公司13661744693 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]
杭州洁汉化工有限公司+86-571-86217390; +8618058761490 · [email protected]
上海易恩化学技术有限公司400-400-1332688 18019345275 · [email protected]
成都圣美凯生物科技有限公司028-85157043 15882256948 · [email protected]
广州千行进出口有限公司020-37651955 13682223272 · [email protected]
宜城永鑫精细化工有限公司+86-0710-4323688 +86-18071785587 · [email protected]
深圳聚合生化科技有限公司+86-400-002-6226 · [email protected]
上海孚一生物科技有限公司18096642264;18096409024 · [email protected]
Aladdin Scientific[email protected]
常州新星联生物科技有限公司+86-0519-85551759 · [email protected]
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.+86-029-86185165 +86-18629664246 · [email protected]
武汉福鑫化工有限公司027-59207852 13308628970 · [email protected]
Yiwu Fengjin Commercial Company+86-19518257926 +86-19164429943 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]